Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biodexa Pharmaceticals (BDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: BDRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.52
1 Year Target Price $18.52
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.34M USD | Price to earnings Ratio - | 1Y Target Price 18.52 |
Price to earnings Ratio - | 1Y Target Price 18.52 | ||
Volume (30-day avg) 1 | Beta 1.21 | 52 Weeks Range 0.78 - 41.50 | Updated Date 07/4/2025 |
52 Weeks Range 0.78 - 41.50 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.41% | Return on Equity (TTM) -88.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3050950 | Price to Sales(TTM) 0.58 |
Enterprise Value 3050950 | Price to Sales(TTM) 0.58 | ||
Enterprise Value to Revenue 4.7 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 5050630 | Shares Floating 22018676243 |
Shares Outstanding 5050630 | Shares Floating 22018676243 | ||
Percent Insiders 1.17 | Percent Institutions 7.7 |
Upturn AI SWOT
Biodexa Pharmaceticals
Company Overview
History and Background
Biodexa Pharmaceuticals PLC (formerly known as Nuerocrine Biosciences) is a biopharmaceutical company focused on developing therapies for patients with unmet medical needs in rare diseases and other specialty indications. Founded in 2007, it has undergone several transformations, including name changes and strategic shifts in its therapeutic focus.
Core Business Areas
- Drug Delivery Technology: Biodexa is focusing on its proprietary drug delivery technologies to improve the bioavailability and efficacy of existing and novel drugs.
- Clinical Development: Biodexa also engages in the clinical development of its drug candidates, primarily focusing on oncology and other specialized areas.
Leadership and Structure
Biodexa Pharmaceticals's leadership team includes key executives in R&D, clinical development, and corporate management. The organizational structure is comprised of functional departments specializing in various areas, such as research, clinical trials, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- MTX110: MTX110 is a formulation of panobinostat for the treatment of recurrent medulloblastoma. There's no available market share data. Key competitors include companies developing treatments for medulloblastoma, and standard chemotherapy regimens.
- Proprietary drug delivery technologies: Biodexa's proprietary technology enhances the absorption of medication in the body. No market share data is available as this is a technology platform with several applications in development.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with a focus on innovation, regulatory compliance, and market access. Drug development is a lengthy and costly process, with a high risk of failure. Smaller companies like Biodexa often focus on niche markets and specialized therapies.
Positioning
Biodexa focuses on niche areas, particularly rare diseases and specialized drug delivery. Its competitive advantage depends on the success of its clinical trials and the marketability of its technologies.
Total Addressable Market (TAM)
The TAM for Biodexa's targeted therapeutic areas is significant, especially in oncology and rare diseases. Biodexa aims to capture a portion of this market through successful drug development and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology
- Focus on unmet medical needs
- Experienced leadership team
- Clinical-stage pipeline
Weaknesses
- Limited financial resources
- High dependence on clinical trial outcomes
- Small market capitalization
- Limited commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through in-licensing or acquisitions
- Advancement of clinical programs to regulatory approval
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- None available based on supplied company
Competitive Landscape
Biodexa faces competition from larger, more established pharmaceutical companies with greater resources and broader pipelines. Its competitive advantage lies in its specialized technologies and focus on unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable and dependent on funding and clinical trial progress.
Future Projections: Future growth depends heavily on the success of clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include focusing on MTX110 and exploring strategic partnerships.
Summary
Biodexa Pharmaceuticals is a small biopharmaceutical company focusing on drug delivery and niche therapeutic areas. Its success hinges on the outcomes of its clinical trials, and its limited financial resources pose a risk. Strategic partnerships and successful commercialization are crucial for its long-term growth. The company faces significant competition from larger pharmaceutical players and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company information
- Public filings
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share and financial data is as current as possible, relying on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodexa Pharmaceticals
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-12-07 | CEO, CFO, Company Secretary & Director Mr. Stephen Anthony Stamp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.biodexapharma.com |
Full time employees 13 | Website https://www.biodexapharma.com | ||
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.